Assyro AI

Purple Book product · Biosimilar 351(k)

Zarxio

filgrastim-sndz

351(k) BiosimilarBLA 125553RxLicensed Sandoz Inc.

At a glance

Mar 06, 2015

Approved

Biosimilar 351(k)

License type

Rx

Marketing

No

Patents listed

Key dates

  1. Approval

    Approval date of this BLA submission.

    Mar 06, 2015

    11 yr 5 mo ago

  2. Today

Pharmaceutical detail

Strength

300MCG/0.5ML

Dosage form

Injection

Route

Intravenous, Subcutaneous

Presentation

Pre-Filled Syringe

Center

CDER

License number

2003

Product number

001

Submission type

Original

Supplement number

Not listed

Change type

Not listed

Reference product family

View full family

Biosimilar of filgrastim (Neupogen)

Patent list

No patent-list records were published for this product. The Purple Book patent list reflects the statutory patent exchange under the BPCIA and is not exhaustive.

Taxonomy and ontology

10 terms

center

Center for Drug Evaluation and Research

center · CDER

application pathway

Biologics License Application

blaNumber · BLA

license type

351(k) Biosimilar

blaType · 351(k) Biosimilar

application pathway

Section 351(k) Biosimilar or Interchangeable

blaType · 351(k)

product role

Biosimilar

blaType · Biosimilar

marketing status

Prescription

marketingStatus · Rx

licensure status

Licensed

licensure · Licensed

dosage form

Injection

dosageForm · Injection

source kind

Monthly Download

sourceKind · monthly_download

patent status

No Patent List Provided

patentListProvided · No patent list

  • Food and Drug Administrationparent ofCenter for Drug Evaluation and Research
  • Food and Drug Administrationsource forMonthly Download
  • Biologics License Applicationparent ofSection 351(a) Biologic
  • Biologics License Applicationparent ofSection 351(k) Biosimilar or Interchangeable
  • Section 351(k) Biosimilar or Interchangeablemaps to351(k) Biosimilar
  • Section 351(k) Biosimilar or Interchangeablemaps to351(k) Interchangeable

Source provenance

Source kind · Monthly download
Checked May 28, 2026
FDA release · April 2026
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.